TACRO UC
Tacrolimus in steroid dependent UC
SWITCH
Infliximab switch to adalimumab in CD
SECUKINUMAB
Secukinumab in mode-severe CD
RIFAXIMIN-CD
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn’s Disease
PODIUM
Mesalazine in UC once or twice daily
IFX postop
Infliximab in postoperative recurrence in CD
IMAgINE 1
Adalimumab in paediatric CD
EXTEND
Adalimumab in CD
Glutamine and whey protein in CD
Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s disease: a randomized controlled trial
CYSIF
Cyclosporin vs infliximab in ASUC